Hims & Hers Stock is Falling Ahead of Earnings. What to Expect.

Dow Jones

14 hours ago

Hims & Hers Health stock was falling on Monday ahead of the telehealth company's third-quarter earnings report.

Shares were down about 10% at $23.39 in late-afternoon trading on Monday, reversing an 8% gain on Friday, when it announced an agreement with pharmaceutical giant Eli Lilly to sell the popular GLP-1 weight loss drugs Zepbound and Foundayo through Hims' consumer platform. The stock is down 28% this year and down 43% over the past 12 months.

Analysts expect Hims to report third quarter earnings of 6 cents a share and revenue of $893 million, according to FactSet. Wall Street is also expecting the telehealth platform to show growth in subscribers to over 3 million, from 2.89 million in the second quarter.

The agreement with Lilly allows users to complete a consultation, receive a prescription if their provider agrees it is appropriate, and have the Lilly treatments shipped straight to their home.

Self-pay pricing starts at $149 a month for Foundayo, an oral medication, and $299 a month for injectable Zepbound.

"Millions of people turn to Hims & Hers for their care, and through this agreement, those patients now have a simple, more direct way to get FDA-approved Lilly medicine at an affordable price if prescribed," Eli Lilly executive Ilya Yuffa said Friday.

Hims & Hers management will discuss results today during a conference call at 5 p.m. Eastern time.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www-web.itiger.com/news/2682833691"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2682833691\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2682833691?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-11-10 04:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2682833691","market":"sh","top_or_hot":-1,"title":"Hims & Hers Stock is Falling Ahead of Earnings. What to Expect.","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     Hims &amp; Hers Health stock was falling on Monday ahead of the telehealth company's third-quarter earnings report. \n</p>\n<p>\n     Shares were down about 10% at $23.39 in late-afternoon trading on Monday, reversing an 8% gain on Friday, when it announced an agreement with pharmaceutical giant Eli Lilly to sell the popular GLP-1 weight loss drugs Zepbound and Foundayo through Hims' consumer platform. The stock is down 28% this year and down 43% over the past 12 months. \n</p>\n<p>\n     Analysts expect Hims to report third quarter earnings of 6 cents a share and revenue of $893 million, according to FactSet. Wall Street is also expecting the telehealth platform to show growth in subscribers to over 3 million, from 2.89 million in the second quarter. \n</p>\n<p>\n     The agreement with Lilly allows users to complete a consultation, receive a prescription if their provider agrees it is appropriate, and have the Lilly treatments shipped straight to their home. \n</p>\n<p>\n     Self-pay pricing starts at $149 a month for Foundayo, an oral medication, and $299 a month for injectable Zepbound. \n</p>\n<p>\n     \"Millions of people turn to Hims &amp; Hers for their care, and through this agreement, those patients now have a simple, more direct way to get FDA-approved Lilly medicine at an affordable price if prescribed,\" Eli Lilly executive Ilya Yuffa said Friday. \n</p>\n<p>\n     Hims &amp; Hers management will discuss results today during a conference call at 5 p.m. Eastern time. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hims & Hers Stock is Falling Ahead of Earnings. What to Expect.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHims & Hers Stock is Falling Ahead of Earnings. What to Expect.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-11-10 04:50</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     Hims &amp; Hers Health stock was falling on Monday ahead of the telehealth company's third-quarter earnings report. \n</p>\n<p>\n     Shares were down about 10% at $23.39 in late-afternoon trading on Monday, reversing an 8% gain on Friday, when it announced an agreement with pharmaceutical giant Eli Lilly to sell the popular GLP-1 weight loss drugs Zepbound and Foundayo through Hims' consumer platform. The stock is down 28% this year and down 43% over the past 12 months. \n</p>\n<p>\n     Analysts expect Hims to report third quarter earnings of 6 cents a share and revenue of $893 million, according to FactSet. Wall Street is also expecting the telehealth platform to show growth in subscribers to over 3 million, from 2.89 million in the second quarter. \n</p>\n<p>\n     The agreement with Lilly allows users to complete a consultation, receive a prescription if their provider agrees it is appropriate, and have the Lilly treatments shipped straight to their home. \n</p>\n<p>\n     Self-pay pricing starts at $149 a month for Foundayo, an oral medication, and $299 a month for injectable Zepbound. \n</p>\n<p>\n     \"Millions of people turn to Hims &amp; Hers for their care, and through this agreement, those patients now have a simple, more direct way to get FDA-approved Lilly medicine at an affordable price if prescribed,\" Eli Lilly executive Ilya Yuffa said Friday. \n</p>\n<p>\n     Hims &amp; Hers management will discuss results today during a conference call at 5 p.m. Eastern time. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMC","symbol_name":"Corgi HIMS 2x Daily ETF","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2682833691","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2682833691","pubTimestamp":1794257400,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Hims & Hers Health stock was falling on Monday ahead of the telehealth company's third-quarter earnings report.Shares were down about 10% at $23.39 in late-afternoon trading on Monday, reversing an 8%","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"HIMC":"Corgi HIMS 2x Daily ETF","THNR":"AMPLIFY WEIGHT LOSS DRUG & TREATMENT ETF","HIMZ":"DEFIANCE DAILY TARGET 2X LONG HIMS ETF","HMYY":"GraniteShares YieldBoost HIMS ETF","HIYY":"YieldMax HIMS Option Income Strategy ETF","HIMS":"Hims & Hers Health Inc.","BK4196":"保健护理服务","GLAM":"Corgi Beauty, Skincare & Aesthetics ETF","HEAL":"Global X HealthTech ETF","HIMY":"Defiance Leveraged Long + Income HIMS ETF"},"translate_title":"Hims & Hers 的股价在盈利前下跌。期待什么。","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIYY":0.6,"THNR":0.6,"HIMC":0.6,"HIMY":0.6,"HIMZ":0.6,"HEAL":0.6,"GLAM":0.6,"HMYY":0.6,"HIMS":1.92},"content_text":"Hims & Hers Health stock was falling on Monday ahead of the telehealth company's third-quarter earnings report. \n\n\n     Shares were down about 10% at $23.39 in late-afternoon trading on Monday, reversing an 8% gain on Friday, when it announced an agreement with pharmaceutical giant Eli Lilly to sell the popular GLP-1 weight loss drugs Zepbound and Foundayo through Hims' consumer platform. The stock is down 28% this year and down 43% over the past 12 months. \n\n\n     Analysts expect Hims to report third quarter earnings of 6 cents a share and revenue of $893 million, according to FactSet. Wall Street is also expecting the telehealth platform to show growth in subscribers to over 3 million, from 2.89 million in the second quarter. \n\n\n     The agreement with Lilly allows users to complete a consultation, receive a prescription if their provider agrees it is appropriate, and have the Lilly treatments shipped straight to their home. \n\n\n     Self-pay pricing starts at $149 a month for Foundayo, an oral medication, and $299 a month for injectable Zepbound. \n\n\n     \"Millions of people turn to Hims & Hers for their care, and through this agreement, those patients now have a simple, more direct way to get FDA-approved Lilly medicine at an affordable price if prescribed,\" Eli Lilly executive Ilya Yuffa said Friday. \n\n\n     Hims & Hers management will discuss results today during a conference call at 5 p.m. Eastern time.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}